Comprehensive Profile of Breakout Ventures (Breakout.vc)
Overview and Entity Identity
Breakout Ventures (operating digitally at breakout.vc) is a early-stage venture capital firm headquartered in San Francisco, California. Founded in 2016, the firm specializes in backing science-driven companies operating at the intersection of biology, chemistry, and technology. Often categorized under deep tech, hard tech, biotech, and tech-bio, Breakout Ventures focuses primarily on seed, Series A, and early-stage growth investments.
The firm's underlying investment philosophy centers on the belief that advances in cellular biology, computational methods, and green chemistry serve as the primary drivers of technological innovation for the coming decade. Breakout Ventures focuses on deploying capital into companies utilizing convergent science to address critical global challenges in human health and environmental sustainability.
History and Organizational Evolution
Breakout Ventures originated from Breakout Labs, an early-stage philanthropic grant program created in 2011 within the Thiel Foundation (established by Peter Thiel). Breakout Labs was managed by Lindy Fishburne and provided non-dilutive, convertible grants to early-stage scientific efforts that were too speculative for commercial venture capital but too commercially focused for traditional academic grants.
In 2016, Breakout Ventures was formally launched as an independent venture capital management firm to provide traditional equity funding and operational scaling for science-based startups:
2017: Breakout Ventures closed its inaugural debut fund (Fund I) with approximately $60 million in capital commitments.
2021: Breakout Ventures closed its oversubscribed Fund II at $112.5 million. Meanwhile, Breakout Labs formally concluded its grant program after supporting over 50 scientific companies across its ten-year tenure.
Ongoing Growth: The firm expanded its assets under management (AUM) and investment network, partnering alongside venture funds such as Founders Fund, Lux Capital, Khosla Ventures, and Formation 8.
What the Entity Does: Core Investment Thesis
Breakout Ventures serves as an institutional investment firm and strategic partner for seed and Series A founders. The firm operates around key core thematic areas:
Human Health: Investing in companies developing therapeutics, precision medicine, multi-functional drug discovery platforms, diagnostics, and AI-driven biological tools.
Sustainability and Clean Energy: Capitalizing companies transforming industrial processes through synthetic biology, carbon capture, bio-manufacturing, and novel materials.
Deep Science Convergence: Supporting platforms that integrate hardware, AI/machine learning models, and biological data processing to solve previously intractable physical and biological problems.
Services and Offerings Provided by Breakout Ventures
While Breakout Ventures is fundamentally a venture capital provider rather than a vendor of commercial off-the-shelf software or hardware products, it offers a suite of structured services, financial capital products, and platform support mechanisms to early-stage founders and institutional limited partners:
1. Capital Financing Products
Seed and Series A Lead Investments: Initial investment checks typically ranging from $1 million to $10 million, with capital reserved for follow-on participation in subsequent financing rounds.
Syndicate and Follow-On Capital: Structuring syndicate networks and bringing co-investors into rounds to ensure portfolio companies meet capitalization requirements through scaling phases.
2. Strategic and Operational Platform Services
Technical and Scientific Advisory: Assisting scientific founders in navigating technical risk, scaling laboratory models into industrial/clinical deployment, and refining intellectual property (IP) strategy.
Commercialization Guidance: Helping technical founders transition from scientific researchers to commercial executive operators, facilitating market positioning and customer acquisition strategy.
Strategic Corporate Access: Connecting portfolio startups with corporate strategics, enterprise customers, regulatory advisors, and late-stage institutional investors needed for commercial scaling.
Talent and Executive Recruitment: Supporting early-stage hires across research, development, regulatory affairs, and commercial operations.
Representative Portfolio Companies and Applications
Breakout Ventures has backed dozens of companies operating across biotechnology, industrial chemistry, and sustainable technology. Notable instances of technologies commercialized by portfolio entities include:
Twelve (formerly Opus 12): Commercializing industrial technologies that transform carbon dioxide emissions into chemicals, materials, and fuels.
Cytovale: Developing medical diagnostic platforms utilizing microfluidics and machine learning to enable rapid, real-time detection of sepsis in emergency departments.
Noetik: Utilizing machine learning and foundational AI models trained on human tissue samples to discover cancer immunotherapies.
ZymoChem: Utilizing biomanufacturing techniques to produce renewable performance chemicals with high yields.
Ecovative Design: Scaling mycelium-based biomaterials for application in plant-based meats, sustainable textiles, and packaging.
Modern Meadow: Engineering bio-fabricated sustainable materials and ingredients.
Copernic Catalysts: Developing catalysts designed to improve the efficiency and reduce emissions of chemical synthesis processes, such as ammonia production.
Firm Leadership
Breakout Ventures is led by experienced investors and operators with deep backgrounds across venture capital, anthropology, biology, and commercial enterprise:
Lindy Fishburne (Managing Partner): Co-founder of Breakout Ventures and former Executive Director of Breakout Labs at the Thiel Foundation.
Investments and Operations Team: Composed of PhD scientists, veteran startup founders, and financial managers experienced in technical diligence and company creation.
Please note: This information is generated by AI. For legal use, verify with company sources.
